Eli Lilly’s next-generation weight-loss drug, retatrutide, has demonstrated clinical trial results showing more than double the weight reduction achieved by the highest dose of Ozempic. The findings were released Wednesday following a phase 3 clinical trial involving more than 1,000 adults diagnosed with type 2 diabetes.
During the 80-week study, participants taking retatrutide experienced substantial weight decreases depending on their dosage. Individuals on the 9-milligram dose lost an average of 44.3 pounds, while those on the 12-milligram dose shed an average of 47.4 pounds. By comparison, participants taking the highest 2-milligram dose of Ozempic lost an average of 20.9 pounds over the same duration.
Beyond weight reduction, retatrutide trial data indicated favorable effects on cardiovascular health markers, including cholesterol and blood pressure improvements. The once-weekly injectable medication also reduced A1C, a key clinical indicator of diabetes risk, by 2.2 percent. In comparison, Ozempic lowered A1C levels by 1.8 percent.
Retatrutide functions as a triple-hormone receptor agonist, mimicking three distinct hunger-regulating hormones: GLP-1, GIP, and glucagon. Current commercial weight-loss medications target fewer pathways. Medications such as Ozempic and Wegovy, manufactured by Novo Nordisk, mimic only GLP-1, which influences bodily functions ranging from brain signaling to muscle, pancreatic, gastric, and hepatic activity, according to the National Institutes of Health. Meanwhile, Eli Lilly’s existing treatments Mounjaro and Zepbound mimic both GLP-1 and GIP, with GIP assisting in blood sugar regulation through insulin stimulation.
The inclusion of glucagon in retatrutide’s mechanism sets it apart by actively promoting fat burning, even during periods of rest. Eli Lilly announced plans to seek regulatory approval for retatrutide from the U.S. Food and Drug Administration in early 2027. Competitor Novo Nordisk is also advancing an experimental combination drug named CagriSema, which anticipates an FDA review by the end of the year.
Neither retatrutide nor CagriSema has received formal FDA approval. Federal regulators have issued warnings that any versions of these experimental medications currently advertised or available online originate from the black market and pose significant health risks.
Currently, FDA-approved treatments in this therapeutic class include Ozempic and Mounjaro for type 2 diabetes management, alongside Wegovy and Zepbound for weight management in individuals classified as overweight or obese. Health officials advise patients to consult qualified healthcare providers to evaluate potential prescription options.
